Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01108497
First received: April 20, 2010
Last updated: June 22, 2016
Last verified: June 2016
  Purpose
We will study gene and protein expression in leukemia cells of children diagnosed with acute leukemia. We hope to identify genes or proteins which can help us grade leukemia at diagnosis in order to: (a) develop better means of diagnosis and (b) more accurately choose the best therapy for each patient.

Condition Intervention
Leukemia
Procedure: Bone Marrow Aspiration

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Gene Expression [ Time Frame: days 0, 8, 22 or 29 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA
bone marrow

Enrollment: 235
Study Start Date: July 2001
Study Completion Date: September 2015
Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible.
Criteria

Inclusion Criteria:1. All children who present at Packard hospital with a new diagnosis or relapse of acute leukemia will be eligible. There is no bias in regards to age range, gender or ethnic background.

2. Signed informed consent

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01108497

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Norman James Lacayo Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01108497     History of Changes
Other Study ID Numbers: PEDSHEM0001  11062  SU-09112009-3881 
Study First Received: April 20, 2010
Last Updated: June 22, 2016
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Leukemia
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on December 09, 2016